524 related articles for article (PubMed ID: 34496872)
1. Single-cell analysis of a tumor-derived exosome signature correlates with prognosis and immunotherapy response.
Wu J; Zeng D; Zhi S; Ye Z; Qiu W; Huang N; Sun L; Wang C; Wu Z; Bin J; Liao Y; Shi M; Liao W
J Transl Med; 2021 Sep; 19(1):381. PubMed ID: 34496872
[TBL] [Abstract][Full Text] [Related]
2. T cell exhaustion assessment algorism in tumor microenvironment predicted clinical outcomes and immunotherapy effects in glioma.
Chen L; Fu B
Front Genet; 2022; 13():1087434. PubMed ID: 36531217
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory response signature score model for predicting immunotherapy response and pan-cancer prognosis.
Chen S; Huang M; Zhang L; Huang Q; Wang Y; Liang Y
Comput Struct Biotechnol J; 2024 Dec; 23():369-383. PubMed ID: 38226313
[TBL] [Abstract][Full Text] [Related]
4. Exosome nanovesicles as potential biomarkers and immune checkpoint signaling modulators in lung cancer microenvironment: recent advances and emerging concepts.
Khan NA; Asim M; Biswas KH; Alansari AN; Saman H; Sarwar MZ; Osmonaliev K; Uddin S
J Exp Clin Cancer Res; 2023 Aug; 42(1):221. PubMed ID: 37641132
[TBL] [Abstract][Full Text] [Related]
5. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma.
Tian M; Yang J; Han J; He J; Liao W
Int Immunopharmacol; 2020 Oct; 87():106821. PubMed ID: 32731180
[TBL] [Abstract][Full Text] [Related]
6. Construction of exosome-related genes risk model in kidney cell carcinoma predicts prognosis and immune therapy response.
Gao C; Huang W; Su Q; Li J; Wang W; Qi Y; Du E; Zhang Z
Aging (Albany NY); 2024 May; 16(9):7622-7646. PubMed ID: 38728235
[TBL] [Abstract][Full Text] [Related]
7. Novel exosome-related risk signature as prognostic biomarkers in glioblastoma.
Ding M; Xu Q; Jin X; Han Z; Jiang H; Sun H; Jin Y; Piao Z; Zhang S
Front Immunol; 2023; 14():1071023. PubMed ID: 36865549
[TBL] [Abstract][Full Text] [Related]
8. Exploration of Novel Immunological Terms in Lung Cancer With Large Populations: Implications for Immunotherapy.
Yao Y; Wang J; Yang F; Gao W
Front Immunol; 2022; 13():924498. PubMed ID: 35844536
[TBL] [Abstract][Full Text] [Related]
9. An immune-related exosome signature predicts the prognosis and immunotherapy response in ovarian cancer.
Zhu K; Ma J; Tian Y; Liu Q; Zhang J
BMC Womens Health; 2024 Jan; 24(1):49. PubMed ID: 38238671
[TBL] [Abstract][Full Text] [Related]
10. Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy.
Naseri M; Bozorgmehr M; Zöller M; Ranaei Pirmardan E; Madjd Z
Oncoimmunology; 2020 Jun; 9(1):1779991. PubMed ID: 32934883
[TBL] [Abstract][Full Text] [Related]
11. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
12. Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo.
Chen Z; You L; Wang L; Huang X; Liu H; Wei JY; Zhu L; Qian W
J Exp Clin Cancer Res; 2018 Aug; 37(1):190. PubMed ID: 30103789
[TBL] [Abstract][Full Text] [Related]
13. Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer.
Yu Y; Zhang W; Li A; Chen Y; Ou Q; He Z; Zhang Y; Liu R; Yao H; Song E
JAMA Netw Open; 2020 Apr; 3(4):e202149. PubMed ID: 32259264
[TBL] [Abstract][Full Text] [Related]
14. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response.
Zhang Z; Wang ZX; Chen YX; Wu HX; Yin L; Zhao Q; Luo HY; Zeng ZL; Qiu MZ; Xu RH
Genome Med; 2022 Apr; 14(1):45. PubMed ID: 35488273
[TBL] [Abstract][Full Text] [Related]
15. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
16. The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation.
Alfonsi R; Grassi L; Signore M; Bonci D
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29652798
[TBL] [Abstract][Full Text] [Related]
17. Exosomes carrying immune checkpoints, a promising therapeutic approach in cancer treatment.
Rasihashemi SZ; Sahrai H; Rezazadeh-Gavgani E; Yazdani Y; Khalaji A; Lotfinejad P
Med Oncol; 2022 Sep; 39(12):183. PubMed ID: 36071295
[TBL] [Abstract][Full Text] [Related]
18. An exosome-related lncRNA signature correlates with prognosis, immune microenvironment, and therapeutic responses in hepatocellular carcinoma.
Peng W; Bai S; Zheng M; Chen W; Li Y; Yang Y; Zhao Y; Xiong S; Wang R; Cheng B
Transl Oncol; 2023 May; 31():101651. PubMed ID: 36933293
[TBL] [Abstract][Full Text] [Related]
19. Exosomes: A potential tool for immunotherapy of ovarian cancer.
Gong X; Chi H; Strohmer DF; Teichmann AT; Xia Z; Wang Q
Front Immunol; 2022; 13():1089410. PubMed ID: 36741380
[TBL] [Abstract][Full Text] [Related]
20. Development of an exosome-related and immune microenvironment prognostic signature in colon adenocarcinoma.
Cui G; Wang C; Liu J; Shon K; Gu R; Chang C; Ren L; Wei F; Sun Z
Front Genet; 2022; 13():995644. PubMed ID: 36176299
[No Abstract] [Full Text] [Related]
[Next] [New Search]
